ClinicalTrials.gg
RecruitingNCT06417437Updated May 16, 2024

Non-invasive BCI and Application Verification for Depressed People

A Phase 4 interventional study of SSRI and rTMS in Depression, Major Depressive Disorder and Bipolar Depression, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Shanghai Mental Health Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2023, registered Apr 2024).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Depression by Shanghai Mental Health Center — 3 open to participants now, 5 under way, none of them phase 3. Depression · Shanghai Mental Health Center.

Planned enrollment
3rd of 11
400 · median 120
Started
2023
with 1 other
Phase 4
3 of 15
1 open now
Registered
12th of 15
by date

Among the 15 studies in Depression by Shanghai Mental Health Center, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 4, and was the 12th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

3 of the 15 studies in Depression by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Depression by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

Major Depressive Disorder (MDD) is a serious mental illness and public health problem that poses threat to both physical and mental health. According to statistics from WHO, it is estimated that more than 350 million people worldwide suffer from depression, with a prevalence rate of 2.1% in China, which is approximately 30 million people.

At present, due to the lack of neurobiological markers for screening and diagnosing depression, the identification and diagnosis of MDD are based on the judgment of professional doctors, and the treatment mostly relies on clinical symptoms.

In terms of treatment, medication remains the main stream for MDD. Although current methods have certain therapeutic effects, patients still suffer from various side effects and poor cognitive function.In current clinical practice, relying purely on symptomatic diagnosis and treatment is difficult to meet the needs of clinical practice, so there is an urgent need to search for neurobiological markers in depression and develop targeted non-invasive intervention technologies.

This study aims to combine advanced brain imaging technology, digital twin-brain models, multi-source information decoding technology, integrated detection and intervention technology. The target is to create two new types of non-invasive BCI systems that can regulate emotions. One is a intervention BCI system for MDD that is suitable for hospital settings with the purpose of precise physical stimulation, and the other one is an ecological BCI system that regulate emotions and intervene with depression which is suitable for both hospital settings and future family environments.

This study will collect a comprehensive collection of physiological and biochemical indicators from patients with depression and from healthy control groups, as well as multimodal information such as head surface electroencephalography, MRI, and eye movements under different brain states, to personalize the available BCI information of depression related brain regions, circuits, and networks. The study also tries to explore emotional-interactive games that can intervene with depression and build a game data base that is dedicated to MDD. Other goals include designing and establishing two new types of emotional regulation systems, which are precise external physical stimulation intervention and ecological intervention, constructing a BCI regulation system, and conducting application verification to evaluate the regulation effect.

Read the detailed description

This study aims to establish a BCI regulation scheme and system for individuals with mdd, and to conduct validation for this application. Four more detailed contents are being designed, including 1. providing biological markers in brain regions, circuits, and networks that are probably related to MDD, 2. assessment models of the state of brain and multivariate signal mapping models, 3. virtual regulation paradigms, evaluations on the effect of the regulation , and 4. multimodal information collection and regulation software and hardware technologies.

Shanghai Mental Health Center, as the sponsor institution, tends to recruit MDD patients from daily outpatient service. The paticipants' personal information will be noted and then the patients will undergo different assessment on their level of depression, anxiety, anhedonia, manic state, cognitive status, effect and side effects of the current treatment, and their biological rhythm, sleep, quality of life, etc. Peripheral blood will be drawn for different potential biomarkers, as well as multimodal information such as EEG, eye movement, magnetic resonance imaging, magnetoencephalogram, fNIRS, and etc. Then compare the following laboratory indicators between depressed patients and healthy individuals such as differences in the concentration and gene expression of peripheral blood inflammatory factors, oxidative stress indicators, brain-derived neurotrophic factors, brain imaging, electrophysiology, blood oxygen and etc. The work above is to obtain specific neurobiological markers of MDD.

Intervention measures are as follows:

  1. Traditional medication with SSRIs. MDD patients will be give different SSRIs medication and undergo a two-week treatment, after which the above assessments will be done again to evaluation the efficacy and side effects of the current treatment. For MDD patients with anhedonia, other medication can be considered such as Voxetine and Bupropion.
  2. rTMS combined with traditional SSRIs medication. The current brain regions chosen for rTMS include dorsolateral pre-frontal cortex. In this part, the study tends to find out new potential brain regions suitable for physical treatment in MDD patients. The considered brain regions include orbitofrontal cortex, cerebellum and others. It uses a classic 8-shaped coils, butterfly coils, deep coils, etc., neural navigation to locate stimulation targets.
  3. Treatment based on neurobiological feedback. In this kind of treatment, MDD patients are treated with neurobiological feedback and will be monitored by EGG to catch unique and specific brain waves that may considered only found in MDD patients. This treatment involves using different psychological paradigms including classic cognitive research paradigms to evaluate the outcome of neuron-training and cognitive function after treatment.

Other technologies used in this study includes:

  1. Functional Magnetic Resonance Imaging. Brain images will be captures during different functional tasks such as emotional matching, Monetary Incentive Delay Task ( MID ). These images will be further analyzed to figure out the neuro-mechanism of MDD. We will be using 3T Siemens PRISMA, collecting data of rs-fMRI、DTI、T1、T2 and fMRI.
  2. Electroencephalography. In this part, the investigators will be using the DSI-24 wireless dry electrode EEG system. Each subject will undergo EEG collection experiments, at least collecting EEG data in a resting state (with eyes closed and open).
  3. Eye movement detection. Eye movement will be traced using Tobii Pro Spectrum.
  4. Functional Near-Infrared Spectroscopy. Patients will perform different tasks under the monitoring of a portable fNIRS device called Nirsport2 wireless wearable NIRS imaging system. It consists of a 8-channel LED illuminator and 8-channel active sensor for fiberless optical detection. During the tasks, the device will provide the value and changes in the level of oxyhemoglobin and deoxygenated hemoglobin observed in the subjects.
  5. Magnetoencephalogram. MEG is a completely non-invasive function detection technique, widely used in the development and research of brain function and the clinical diagnosis of brain diseases. MEG uses a sensitive magnetic sensor SQUID (Superconducting Quantum Interferometer), which is placed around the head to measure the abnormally weak magnetic field generated by neuronal activity. The detected magnetic signal data will then be analyzed and processed by a computer and superimposed on magnetic resonance imaging (MRI). Through software 3D imaging, the results can be more intuitive, making the MEG have extremely high temporal and spatial resolution.

MDD patients will be divided into different treatment gourds based on theirs condition and whether the chosen treatment would be the most suitable for them. All individuals will undergo the above assessments to establish a comprehensive, multimodal information data base, and finally after comparing the outcome before and after the treatment, the study tries to find out new and effective measures and validate their feasibility.

03

Conditions studied

  • Depression
  • Major Depressive Disorder
  • Bipolar Depression
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 12 years old, male or female, right-handed, Han ethnicity
  • Meets the diagnostic criteria for depression, with HAMD-17 scores greater than 17 and YMRS scores less than 6;
  • Primary school education or above, able to understand the research content, willing to participate in this study and sign an form

Exclusion criteria

Exclusion Criteria:

  • Concomitant or previous history of organic brain disease or severe traumatic brain injury, personal or family history of epilepsy;
  • Severe abnormalities in heart, liver, and kidney function;
  • Patients with severe physical illnesses;
  • History of substance dependence or abuse (alcohol, cocaine, drugs, etc.);
  • Patients with mental disorders caused by organic diseases, drug or alcohol induced mental disorders, and other mental disorders;
  • Pregnancy or lactation period;
  • Within six months, physical therapy such as MECT and TMS should be used;
  • Implants of vegetative nerve stimulation;
  • Individuals who have implanted electronic or metal instruments (such as pacemakers, defibrillators, stents, orthopedic plates, etc.) and undergo ventriculoperitoneal shunt surgery;
  • Obvious visual and auditory impairment, unable to cooperate in completing neuropsychological and scale assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Medication Group

    Patients with anhedonia will be using either Bupropion or Voxetine. Patients without anhedonia will be given SSRIs. Frequency and dosage will be guided by psychiatrist. Treatment will last 4 weeks.

    Drug: SSRI

  • Experimental
    Traditional rTMs Group

    In addition to medication using SSRIs, patients will be also treated with rTMS. The stimulated brain region has decided to be dlpfc. Treatment will last 4 weeks.

    Drug: SSRI · Device: rTMS

  • Experimental
    New rTMS Group

    In addition to medication using SSRIs, patients will be also treated with rTMS. The stimulated brain region has not been decided, but rbitofrontal cortex, cerebellum and others are considered. Treatment will last 4 weeks.

    Drug: SSRI · Device: rTMS

  • Experimental
    Neuro-Feedback Group

    In addition to medication using SSRIs, patients will be also treated with Neuro-Training. The process will be guided under fNIRS and monitored by EGG. Treatment will last 4 weeks.

    Drug: SSRI · Behavioral: Neuro-Feedback

  • Experimental
    Game-regulation Group

    In addition to medication using SSRIs, patients will be also treated with games that can regulate emotions. Details are not yet decided. Treatment will last 4 weeks.

    Drug: SSRI · Behavioral: Game Regulation

Interventions

  • DrugSSRIsStudies of SSRIsSSRIs pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.

  • DevicerTMS

    Patients will be treated targeting either the traditional brain region or new region.

  • BehavioralNeuro-Feedback

    Patients under 18 years old will first be considered this treatment before other methods.

  • BehavioralGame Regulation

    Patients will learn how to play several games that can supposedly regulate or affect negative emotions.

06

What researchers measure

Primary outcomes

  1. EEG power in alpha band between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by EEG at 2 weeks.

    Time frame: 2 weeks

  2. EEG power in beta band between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by EEG at 2 weeks.

    Time frame: 2 weeks

  3. MRI imaging of DLPFC between the depression patient group and healthy controls.

    Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 2 weeks.

    Time frame: 2 weeks

  4. HbO in fNIRS between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by fNIRS at 2 weeks.

    Time frame: 2 weeks

  5. Hb in fNIRS between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by fNIRS at 2 weeks.

    Time frame: 2 weeks

  6. EEG power in alpha band between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by EEG at 4 weeks.

    Time frame: 4 weeks

  7. EEG power in beta band between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by EEG at 4 weeks.

    Time frame: 4 weeks

  8. MRI imaging of DLPFC between the depression patient group and healthy controls.

    Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 4 weeks.

    Time frame: 4 weeks

  9. HbO in fNIRS between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by fNIRS at 4 weeks.

    Time frame: 4 weeks

  10. Hb in fNIRS between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by fNIRS at 4 weeks.

    Time frame: 4 weeks

  11. EEG power in alpha band between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by EEG at 8 weeks.

    Time frame: 8 weeks

  12. EEG power in beta band between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by EEG at 8 weeks.

    Time frame: 8 weeks

  13. MRI imaging of DLPFC between the depression patient group and healthy controls.

    Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 8 weeks.

    Time frame: 8 weeks

  14. HbO in fNIRS between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by fNIRS at 8 weeks.

    Time frame: 8 weeks

  15. Hb in fNIRS between the depression patient group and healthy controls.

    Changes from baseline in multimodal emotional data as assessed by fNIRS at 8 weeks.

    Time frame: 8 weeks

  16. The score of HAMD-17 in depression patient group and healthy controls.

    Changes from baseline in the score of HAMD-17 at 2 weeks

    Time frame: 2 weeks

  17. The score of HAMD-17 in depression patient group and healthy controls.

    Changes from baseline in depression patient group in the score of HAMD-17 at 4 weeks

    Time frame: 4 weeks

  18. The score of HAMD-17 in depression patient group and healthy controls.

    Changes from baseline in depression patient group in the score of HAMD-17 at 8 weeks

    Time frame: 8 weeks

Secondary outcomes

  1. The change in the state of depression in depression patient groups

    The state of depression in patient group measured by SDS(0-80) at 2 weeks.

    Time frame: 2 weeks

  2. The change in the state of agitation in depression patient groups

    The state of depression in patient group measured by HCL-32(0-32) at 2 weeks.

    Time frame: 2 weeks

  3. The change in the state of depression in depression patient groups

    The state of depression in patient group measured by SDS(0-80) at 4 weeks.

    Time frame: 4 weeks

  4. The change in the state of agitation in depression patient groups

    The state of depression in patient group measured by HCL-32(0-32) at 4 weeks.

    Time frame: 4 weeks

  5. The change in the state of depression in depression patient groups

    The state of depression in patient group measured by SDS(0-80) at 8 weeks.

    Time frame: 8 weeks

  6. The change in the state of agitation in depression patient groups

    The state of depression in patient group measured by HCL-32(0-32) at 8 weeks.

    Time frame: 8 weeks

  7. The change in the state of anhedonia in depression patient groups

    The state of depression in patient group measured by SHAPS(0-64) at 2 weeks.

    Time frame: 2 weeks

  8. The change in the state of anhedonia in depression patient groups

    The state of depression in patient group measured by SHAPS(0-64) at 4 weeks.

    Time frame: 4 weeks

  9. The change in the state of anhedonia in depression patient groups

    The state of depression in patient group measured by SHAPS(0-64) at 8 weeks.

    Time frame: 8 weeks

  10. The change in the state of anxiety in depression patient groups

    The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 2 weeks.

    Time frame: 2 weeks

  11. The change in the state of anxiety in depression patient groups

    The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 4 weeks.

    Time frame: 4 weeks

  12. The change in the state of anxiety in depression patient groups

    The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 8 weeks.

    Time frame: 8 weeks

  13. The change in the level of cognitive function in depression patient group

    The level of cognitive function in patient group measured by RBANS at 2 weeks.

    Time frame: 2 weeks

  14. The change in the level of cognitive function in depression patient group

    The level of cognitive function in patient group measured by RBANS at 4 weeks.

    Time frame: 4 weeks

  15. The change in the level of cognitive function in depression patient group

    The level of cognitive function in patient group measured by RBANS at 8 weeks.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2027, 48 months after the start.

Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
May 16, 2024
StartActual
Jul 1, 2023
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06417437
Collaborators
The Fourth People's Hospital of Chengdu, Shanghai Jiao Tong University School of Medicine, University of Electronic Science and Technology of China, East China Normal University
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Jul 1, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
May 16, 2024

Study contacts

Zhenghui Yi, chief physician
Contact
yizhenghui1971@163.com
18017311007
Qinyu Lv, chief physician
Contact
lvqinyu_louis@163.com
18616550357
Zhenghui Yi, chief physician
study chair · Shanghai Mental Health Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion